Maze Therapeutics (NASDAQ:MAZE) CEO Sells $621,683.25 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 23,865 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $26.05, for a total transaction of $621,683.25. Following the completion of the transaction, the chief executive officer directly owned 319,079 shares in the company, valued at $8,312,007.95. This represents a 6.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Up 5.2%

Shares of Maze Therapeutics stock opened at $28.43 on Friday. Maze Therapeutics, Inc. has a one year low of $10.98 and a one year high of $53.65. The company has a market cap of $1.57 billion, a P/E ratio of -11.24 and a beta of 2.26. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The firm has a fifty day moving average of $25.68 and a two-hundred day moving average of $35.98.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. On average, analysts forecast that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Royal Bank of Canada increased its holdings in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. boosted its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MAZE shares. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright lifted their price target on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. JPMorgan Chase & Co. lifted their price target on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Guggenheim increased their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.